Price Alert

Poseida Therapeutics Inc. (PSTX)

NASDAQ: PSTX · Real-Time Price · USD

9.50

0.00 (0.00%)

At close: Jan 07, 2025, 10:00 PM

Poseida Therapeutics Statistics

Share Statistics

Poseida Therapeutics has 97.47M shares outstanding. The number of shares has increased by 0.34% in one year.

Shares Outstanding	97.47M
Shares Change (YoY)	0.34%
Shares Change (QoQ)	0%
Owned by Institutions (%)	55.06%
Shares Floating	64.7M
Failed to Deliver (FTD) Shares	600
FTD / Avg. Volume	0.03%

Short Selling Information

The latest short interest is 3.55M, so 0% of the outstanding shares have been sold short.

Short Interest	3.55M
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.83

Valuation Ratios

The PE ratio is -2.46 and the forward PE ratio is -5.25. Poseida Therapeutics's PEG ratio is -0.05.

PE Ratio	-2.46
Forward PE	-5.25
PS Ratio	4.68
Forward PS	21
PB Ratio	2.92
P/FCF Ratio	-3.18
PEG Ratio	-0.05

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Poseida Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.18, with a Debt / Equity ratio of 0.82.

Current Ratio	3.18
Quick Ratio	3.18
Debt / Equity	0.82
Debt / EBITDA	-0.78
Debt / FCF	-0.9
Interest Coverage	-14.94

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$184.87K
Profits Per Employee	$-352.66K
Employee Count	350
Asset Turnover	0.24
Inventory Turnover	n/a

Taxes

Income Tax	107K
Effective Tax Rate	-0.09%

Stock Price Statistics

The stock price has increased by 228.72% in the last 52 weeks. The beta is 0.54, so Poseida Therapeutics's price volatility has been higher than the market average.

Beta	0.54
52-Week Price Change	228.72%
50-Day Moving Average	6.66
200-Day Moving Average	3.82
Relative Strength Index (RSI)	75.33
Average Volume (20 Days)	1,798,028

Income Statement

In the last 12 months, Poseida Therapeutics had revenue of 64.7M and earned -123.43M in profits. Earnings per share was -1.37.

Revenue	64.7M
Gross Profit	-92.07M
Operating Income	-129.5M
Net Income	-123.43M
EBITDA	-109.04M
EBIT	-114.65M
Earnings Per Share (EPS)	-1.37

Full Income Statement

Balance Sheet

The company has 44.47M in cash and 85.42M in debt, giving a net cash position of -40.95M.

Cash & Cash Equivalents	44.47M
Total Debt	85.42M
Net Cash	-40.95M
Retained Earnings	-594.29M
Total Assets	293.58M
Working Capital	172.44M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -92.17M and capital expenditures -3.07M, giving a free cash flow of -95.23M.

Operating Cash Flow	-92.17M
Capital Expenditures	-3.07M
Free Cash Flow	-95.23M
FCF Per Share	-1.06

Full Cash Flow Statement

Margins

Gross margin is -142.29%, with operating and profit margins of -200.15% and -190.76%.

Gross Margin	-142.29%
Operating Margin	-200.15%
Pretax Margin	-190.6%
Profit Margin	-190.76%
EBITDA Margin	-168.52%
EBIT Margin	-200.15%
FCF Margin	-147.18%

Dividends & Yields

PSTX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for PSTX is $9, which is -5.3% lower than the current price. The consensus rating is "Hold".

Price Target	$9
Price Target Difference	-5.3%
Analyst Consensus	Hold
Analyst Count	3

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	0.33
Piotroski F-Score	4